Patent ID: 11931382
Assignee: IMMUNITYBIO, INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C | IPC A  C

Claim 14:
15. A method of producing a population of CIK NKT cells from a blood sample, in which greater than 90% of the CIK NKT cells express CD56 and CD3 and less than 10% of the CIK NKT cells express Va24, the method comprising: 1) isolating mononuclear cells from the blood sample; and contacting the isolated mononuclear cells with IL-7, ALT-803 or IL-15, or FLT3 ligand, and Gal-Cer, thereby enriching the CIK NKT cells; 2) isolating the enriched CIK NKT cells from the rest of the blood sample; and 3) expanding the isolated CIK NKT cells with anti-CD3, anti-CD28, IL2, and Gal-Cer.